Companies Related to "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017" [Most Relevant Company Matches] RSS

02:15 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017" found in our extensive corporate database of over 50,000 company records.

Showing "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017" Companies 1–25 of 1,900+

Extremely Relevant

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. A Phase 1B clinical trial evaluating its oral small molecule checkpoint inhib...


FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

Checkpoint Surgical, Inc.

Checkpoint Surgical is a privately held, Cleveland, Ohio based medical device company committed to providing surgeons with user-friendly, cost-effective devices to protect and repair nerve intraoperatively across the anatomy. At Checkpoint Surgical, our mission is to advance the science and practice of nerve protection and repair to improve the quality of ...

Innate Immunotherapeutics Limited

Innate Immunotherapeutics Limited is a public unlisted biopharmaceutical company based in Auckland, New Zealand. The company is focused on the development of a new generation of immune response modifiers for potential use in the treatment of MS and other autoimmune diseases, a range of infectious diseases, certain cancers, and as a novel cellular and humor...

CBT Pharmaceuticals, Inc.

CBT Pharmaceuticals is a biopharmaceutical company focused on developing innovative oncology therapeutics harnessing the immune system and targeting specific molecular pathways to tame cancer. The company is advancing a pipeline of four development-stage assets. CBT-101, is an oral c-MET inhibitor targeting the epithelial to mesenchymal transition (EMT) pa...

Checkpoint Systems, Inc.

Checkpoint Systems is a global leader in merchandise availability solutions for the retail industry, encompassing loss prevention and merchandise visibility. Checkpoint provides end-to-end solutions enabling retailers to achieve accurate real-time inventory, accelerate the replenishment cycle, prevent out-of-stocks and reduce theft, thus improving merchand...

Brooklyn ImmunoTherapeutics LLC

Brooklyn ImmunoTherapeutics (formerly IRX Therapeutics) is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies.

ACT Biotech Inc.

ACT Biotech ( is a San Francisco-based, privately-held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs. The Company's clinical stage pipeline also includes Telatinib, the most selective oral VEGF/PDGFR/KIT inhibitor ever developed. Telatinib is currently being studied in a Phase 2 trial...

Checkmate Pharmaceuticals, Inc.

Checkmate Pharmaceuticals is a research and development company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging their expertise and the vast body of knowledge in the field of CpG oligonucleotides and is validating an approach that will combine ...

Avant Immunotherapeutics

AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines against viral and bacterial diseases, including single-dose oral vaccines aimed a protecting travelers from cholera, typhoid fever and other illnesses. In addition, the co...

Kyn Therapeutics

Kyn Therapeutics is a biotechnology company advancing new immunometabolic therapies for cancer. A growing body of research indicates that key metabolites can exert broad suppressive or enhancing effects on the immune system through a complex network of cellular interactions, providing targets for new therapies that could significantly enhance patient respo...

Celldex therapeutics

Celldex is a biotechnology company focused on the discovery, development and commercialization of novel immunotherapeutics including human monoclonal antibodies for the treatment of cancer, infectious diseases, and immune system disorders. We are advancing a pipeline of clinical and pre-clinical product candidates.Our proprietary core technology utilizes human monoclonal antibodies to directly tar...

TeGenero AG

June 2000Company inception TeGenero is a biopharmaceutical company dedicated to the identification and development of innovative, highly effective and broadly applicable immunotherapeutics.We strive to provide patients the means to regain a functional and balanced immune system.

Tizona Therapeutics, Inc.

Tizona Therapeutics, Inc., is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system’s function. In cancer, tumor cells evade recognition by c...

CBT Pharmaceuticals

CBT Pharmaceuticals is a life sciences company developing innovative oncology therapeutics targeting the growth and proliferation of cancer cells. The company is advancing a pipeline of four development-stage assets including CBT-101, an oral c-Met inhibitor targeting the epithelial-mesenchymal transition (EMT) pathway in cancers and CBT-501, a novel human...

TILT Biotherapeutics Ltd

TILT Biotherapeutics is the leading company globally working in the area of enabling tumor T-cell therapy (including checkpoint antibodies) with oncolytic viruses. The company’s patented technology is uniquely based on human observations on the effect of oncolytic adenoviruses on the adaptive immune system.

Molecular Innovations Incorporated

Plasminogen Activator Inhibitor 1 (PAI-1)FibronectinPolyclonal AntibodiesMonoclonal AntibodiesImmobilized ProteinsELISA ASSAYSOther ReagentsVitronectinRelated Protein Reagents

Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer...

Selexis SA and OSE Immunotherapeutics SA

Our ambition is to become a world leader in activation and regulation immunotherapies: OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies of activation and regulation in immuno-oncology, autoimmune diseases and transplantation. The company has a balanced portfolio ...

The Angeles Clinic and Research Institute

“The Angeles Clinic and Research Institute’s mission is to advance cancer care through groundbreaking research and delivering innovative therapeutic options to all of our cancer patients. As a result of our break-through work, we currently are involved in clinical trials for multiple immune-checkpoint inhibitors,” Dr. Piro noted. “Moreo...

Immune Design Corp.

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors,...

Checkpoint Systems

Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell va...

OSE Immunotherapeutics

Artielle ImmunoTherapeutics

More From BioPortfolio on "Immunotherapeutics Immune Checkpoint Inhibitor Effi 24th Molecular 2017"

Quick Search


Corporate Database Quicklinks